Wall Street Strategies
Hello! Sign in or Register


Big Pharma Needs Smarter Regulations

10/17/2017
By Charles Payne, Principal Analyst & CEO

President Trump spent a lot of time talking about prescription drug prices yesterday. While it’s a topic that hits home for just about everyone, there are big differences between the largess of health care insurers and drug makers. 

Publicly traded giants in Big Pharma peaked long ago in the midst of the blockbuster drug craze, which brought in huge moneymakers, but resulted in thin pipelines and an avalanche of cheap generic alternatives thereafter.

Shares of the biggest names in pharmaceuticals have a long way to go to get back to their all-time highs, having peaked a long time ago.

Big Pharma 

Close

High

Date

GSK

$40.86

$69.50

Dec 1998

MRK

$63.34

$93.60

Dec 2000

LLY

$85.95

$103.80

Jul 2000

PFE

$35.98

$48.00

Jun 2000

 

The industry needs smarter regulations that will allow them longer shelf-life for patents and easier for competition.  As for pricing vis-a-vis other nations, it just means the prices over there have to go higher. Last year, the top five selling prescription drugs saw limited pricing power and revenue increases, or in some cases, saw total sales decline.

#5. Remicade®

Johnson & Johnson and Merck

Indication(s): Crohn's

  • 2016 sales: $7.829 billion ($6.561 billion J&J + $1.268 billion Merck)
  • 2015 sales: $8.760 billion ($6.966 billion J&J + $1.794 billion Merck)
  • % Change: (10.6%)

#4. Rituxan®

Roche (Genentech) and Biogen

Indication(s): non-Hodgkin’s lymphoma; chronic lymphocytic leukemia

  • 2016 sales: $8.583 billion ($7.268 billion [CHF 7.300 billion] Roche + $1.315 billion Biogen)
  • 2015 sales: $8.354 billion ($7.015 billion [CHF 7.045 billion] Roche + $1.339 billion Biogen)
  • % Change: 2.7%

#3. Enbrel®

Amgen and Pfizer

Indication(s): Rheumatoid arthritis; polyarticular juvenile idiopathic

  • 2016 sales: $8.874 billion ($5.965 billion Amgen + $2.909 billion Pfizer)
  • 2015 sales: $8.697 billion ($5.364 billion Amgen + $3.333 billion Pfizer)
  • % Change: 2.0%

#2. Harvoni®

Sponsor(s): Gilead Sciences

Indication(s): indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection

  • 2016 sales: $9.081 billion
  • 2015 sales: $13.864 billion
  • % Change: (34.5%)

#1. Humira® (adalimumab)

Sponsor(s): AbbVie

Indication(s): moderate to severely active rheumatoid arthritis (RA

  • 2016 sales: $16.078 billion
  • 2015 sales: $14.012 billion
  • % Change: 14.7%

Source: https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868

Charles Payne
Wall Street Strategies


 

Add a Comment!

Name:
Email:
Comment:
 
 
Submitted comments are subject to moderation before posting.


Home | Products & Services | Education | In The Media | Help | About Us |
Disclaimer | Privacy Policy | Terms of Use |
All Rights Reserved.